Trade BioCryst - BCRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.47 |
| Open | 7.4 |
| 1-Year Change | 45.96% |
| Day's Range | 7.21 - 7.45 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 7.47 | -0.19 | -2.48% | 7.66 | 7.66 | 7.43 |
| Mar 28, 2025 | 7.83 | 0.05 | 0.64% | 7.78 | 7.89 | 7.65 |
| Mar 27, 2025 | 7.79 | 0.01 | 0.13% | 7.78 | 7.85 | 7.72 |
| Mar 26, 2025 | 7.77 | -0.15 | -1.89% | 7.92 | 8.00 | 7.72 |
| Mar 25, 2025 | 8.04 | 0.04 | 0.50% | 8.00 | 8.07 | 7.82 |
| Mar 24, 2025 | 8.01 | -0.04 | -0.50% | 8.05 | 8.09 | 7.91 |
| Mar 21, 2025 | 7.96 | 0.37 | 4.87% | 7.59 | 8.06 | 7.57 |
| Mar 20, 2025 | 7.65 | 0.14 | 1.86% | 7.51 | 7.68 | 7.51 |
| Mar 19, 2025 | 7.59 | 0.00 | 0.00% | 7.59 | 7.67 | 7.40 |
| Mar 18, 2025 | 7.60 | -0.06 | -0.78% | 7.66 | 7.67 | 7.49 |
| Mar 17, 2025 | 7.70 | 0.04 | 0.52% | 7.66 | 7.77 | 7.48 |
| Mar 14, 2025 | 7.66 | 0.08 | 1.06% | 7.58 | 7.70 | 7.53 |
| Mar 13, 2025 | 7.51 | -0.14 | -1.83% | 7.65 | 7.71 | 7.47 |
| Mar 12, 2025 | 7.68 | 0.19 | 2.54% | 7.49 | 7.91 | 7.49 |
| Mar 11, 2025 | 7.50 | 0.21 | 2.88% | 7.29 | 7.63 | 7.17 |
| Mar 10, 2025 | 7.34 | -0.18 | -2.39% | 7.52 | 7.57 | 7.22 |
| Mar 7, 2025 | 7.64 | -0.19 | -2.43% | 7.83 | 7.93 | 7.55 |
| Mar 6, 2025 | 7.82 | -0.07 | -0.89% | 7.89 | 7.96 | 7.71 |
| Mar 5, 2025 | 8.01 | -0.20 | -2.44% | 8.21 | 8.32 | 7.87 |
| Mar 4, 2025 | 8.26 | 0.30 | 3.77% | 7.96 | 8.35 | 7.64 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioCryst Company profile
BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines.
The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies.
The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.
BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.
The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000.
You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.
| Industry: | Bio Therapeutic Drugs |
4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com